22.75 +0.02 (0.09%)
After hours: 7:14PM EDT
|Bid||20.60 x 800|
|Ask||22.75 x 1800|
|Day's Range||21.71 - 22.84|
|52 Week Range||11.90 - 23.50|
|Beta (3Y Monthly)||0.08|
|PE Ratio (TTM)||841.85|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.29|
On October 3, Vanda Pharmaceuticals (VNDA) stock rose 2.42% to reach $22.84 from its October 2 close of $22.30. Vanda Pharmaceuticals’ October 3 stock price was up 92.0% from its 52-week low of $11.90 on November 13, 2017. Vanda Pharmaceuticals’ stock price reached $22.84 on October 3 from $15.30 at the open of the market on January 2, reflecting ~49.0% YTD (year-to-date) growth. Vanda Pharmaceuticals hit its 52-week high of $23.50 on September 26.
Insys Therapeutics’ (INSY) product pipeline includes cannabidiol oral solution and dronabinol inhalation. It also includes naloxone and epinephrine nasal sprays, buprenorphine and naloxone spray, and buprenorphine sublingual spray.
WASHINGTON , Sept. 26, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming 2018 investor conferences: The Oppenheimer ...
Stocks gave up all their gains and closed well in the red Wednesday, after the Federal Reserve hiked interest rates by a quarter-point, as widely expected.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sept. 25) Abbott Laboratories (NYSE: ABT ) Amarin Corporation ...
NEW YORK , Sept. 25, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: S&P MidCap 400 constituent Rollins Inc. (NYSE: ROL) ...
WASHINGTON , Sept. 20, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that a HETLIOZ ® patent, number 10,071,977 ('977 patent), is now listed in the U.S. Food and ...
Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Vanda Pharmaceuticals Inc (NASDAQ:VNDA) due to its excellent fundamentals in moreRead More...
WASHINGTON , Sept. 12, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results of a HETLIOZ ® (tasimelteon) driving study to measure next day performance. Tasimelteon ...
WASHINGTON , Sept. 4, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in September 2018 : ...
U.S. Court of Appeals Denies Petitions for Panel Rehearing and Rehearing En Banc WASHINGTON , Aug. 14, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. ...
WASHINGTON , Aug. 13, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has named Timothy Williams as Vanda's Senior Vice President, General Counsel and Secretary. ...
Zacks.com highlights: G-III Apparel Group, Rocky Brands, Vail Resorts, Vanda Pharmaceuticals and IntriCon
We create a strategy that clearly shows that less risky stocks can also generate handsome returns if some parameters are considered.
Vanda (VNDA) delivered earnings and revenue surprises of 600.00% and -0.11%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Washington-based company said it had net income of 9 cents. Earnings, adjusted for stock option expense and non-recurring costs, were 14 cents per share. The results topped Wall ...
- Total net product sales were $47.4 million in the second quarter of 2018 - Hetlioz® net product sales grew to $28.0 million in the second quarter of 2018 - Fanapt® net product sales grew to $19.3 million ...
Endocyte (ECYT) initiates a phase III VISION study for its lead pipeline candidate,-177Lu-PSMA-617, during the second quarter of 2018.
The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group